Long-term feto-maternal microchimerism suggests that immune tolerance exists between mother and child. Based on this hypothesis, we have previously performed human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (SCT) without T-cell depletion (TCD) between noninherited maternal antigen (NIMA)-mismatched family members after reduced-intensity as well as conventional myeloablative conditionings.
1,2 Here, we reported a patient with MDS/overt leukemia who was successfully treated with the second non-TCD HLAhaploidentical reduced-intensity conditioning stem cell transplantation (RIST) from the older son for late graft failure after the first non-TCD HLA-haploidentical RIST from the younger son.
A 63-year-old woman was diagnosed as having MDS (refractory anemia excess blasts-2) in February 2004. She could not achieve remission with two courses of induction chemotherapy, and subsequently evolved into overt leukemia in May 2004. Owing to the lack of HLA-matched donor candidates, she received a non-TCD HLA-haploidentical RIST from her younger son in June 2004 ( Table 1 ). The conditioning regimen consisted of fludarabine (Flu) 25 mg/m 2 once daily i.v. from day À6 to day À2 and melphalan (Mel) once daily i.v. on day À3. Graftversus-host disease (GVHD) prophylaxis consisted of tacrolimus (FK506) with mini-dose methotrexate (Mtx). Peripheral blood stem cells (PBSC) were harvested from her younger son, and 2.45 Â 10 6 /kg CD34 þ cells were infused. Granulocyte colony-stimulating factor (G-CSF) was administrated from day 1. Hematopoietic recovery was rapid, and full donor chimerism was observed on day 30. Grade I acute GVHD occurred, but subsided spontaneously. However, she had gradually become pancytopenic, and fluorescent in situ hybridization (FISH) analysis of sex chromosomes showed 74% donor chimerism on day 190. She received donor lymphocyte infusion (DLI) twice on days 254 and 308 with 1.0 and 5.0 Â 10 7 /kg CD3 þ cells, respectively. However, she had shown sustained pancytopenia, and was dependent on frequent red blood cell and platelet transfusions. Nevertheless, she remained in fairly good condition without either any active infections or organ damage. Therefore, she received the second non-TCD haploidentical RIST from the other donor, her elder son, on day 468 after the first SCT ( Table 1) . The conditioning regimen consisted of Flu 25 mg/m 2 once daily i.v. from day À6 to day À2 together with total body irradiation (TBI) 2 Gy twice on day À1 instead of Mel. GVHD prophylaxis and post transplant G-CSF administration were performed in the same manner as the first SCT. PBSC were harvested from her elder son, and 2.63 Â 10 6 /kg CD34 þ cells were infused. Hematopoietic recovery was rapid without any signs of acute GVHD. PCR of informative short tandem repeat regions demonstrated 100% donor chimerism on day 30 after the second SCT. So far, she has been in complete remission without recurrence of graft failure for 4 months after the second SCT.
Graft failure is a serious complication after SCT. There have been several risk factors reported for the graft failure after SCT: donor-recipient HLA or ABO mismatch, unrelated donor, reduced-intensity conditioning, TCD, insufficient number of transplanted stem cells or viral infection. [3] [4] [5] [6] In unrelated marrow transplants, not HLA class II but class I disparity, especially HLA-C, was reported to be associated with graft failure. 7, 8 Other reports suggested that residual recipient NK cells might play an important role in the graft failure. 9 Although graft failure usually occurs within the first 6 months after transplantation, very late onset has also been reported in severe aplastic anemia even after the intensive conditioning. 10 In our patient, late graft failure occurred after the first non-TCD HLA haploidentical SCT despite the sufficient number of infused CD34 þ cells. The possible risk factors for graft failure in our case seemed to be donor-recipient HLA mismatch and reduced-intensity conditioning. Anti-HLA antibodies against the first donor were not detected in the peripheral blood of the recipient using a panel reactive antibody method.
Many issues have remained unresolved concerning the management of the graft failure. For example, which therapeutic strategy should be recommended among growth factor, DLI and the second SCT. Moreover, if available, which kind of donor as well as conditioning regimen should be recommended for the second SCT. Our patient did not show the significant unfavorable clinical features for the second SCT except her age, and the immunologic mechanism might be ascribed to her graft failure after the first SCT. Therefore, we performed the second non-TCD RIST from the different child with TBI containing regimen. As anti-thymocyte globulin (ATG) might increase the risk for viral infection after SCT as well as TCD, we did not employ ATG containing regimen. This is the first report of a patient who was successfully treated with the second non-TCD HLA-haploidentical RIST from the different family donor because of the late graft failure after the first non-TCD HLA-haploidentical RIST based on feto-maternal microchimerism. Many more cases will be necessary in order to understand the mechanism as well as the management of the graft failure after non-TCD HLA-haploidentical SCT. 
